War on Big Pharma: How Donald Trump is betting on ‘biosimilar’ generic drugs

The FDA has drastically cut the time for biosimilar drug approval, aiming to halve the market entry period. This move by the Trump administration targets high biologic drug prices by fostering competition. The reform allows for analytical data to replace extensive human trials, potentially lowering costs for patients and payers while challenging Big Pharma’s market dominance.